New hope for tough blood cancers: early trial tests novel drug
NCT ID NCT03770429
Summary
This early-stage study is testing the safety and best dose of an experimental drug called AZD6738 for adults with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has progressed after initial treatment. The drug works by blocking a specific protein in cancer cells that helps them repair damage, aiming to stop their growth. The main goal is to see how well patients tolerate the drug and to check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BIDMC
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02215, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.